问题 › 我们不知道哪些产品能赚钱 › HealthTech & Digital Health
每个数字健康产品组合里都有一份合同，大家都以为它在盈利，而它通常正被风险收入分成补贴着。 数字健康公司面临的结构性难题是：结果风险签约速度快于公司判断自身能否承担的能力——12个月的测量窗口对上11个月的销售周期。因此任何可信的答案都必须同时纳入风险收入分成和参与率，而这正是大多数内部分析止步的地方，因为这两者分属不同系统。
每个数字健康产品组合里都有一份合同，大家都以为它在盈利，而它通常正被风险收入分成补贴着。 数字健康公司面临的结构性难题是：结果风险签约速度快于公司判断自身能否承担的能力——12个月的测量窗口对上11个月的销售周期。因此任何可信的答案都必须同时纳入风险收入分成和参与率，而这正是大多数内部分析止步的地方，因为这两者分属不同系统。
按产品归因利润很难，因为多数成本在已注册成员间分摊，而按收入或PMPM分配通常会锁定答案。按收入比例分摊间接费用会让高收入产品线显得昂贵、低收入产品线显得高效，这恰恰反转了事实——低收入产品线往往通过参与率管理消耗了不成比例的注意力。
可行的做法只分配真正可追溯的成本，例如与归因结果直接挂钩的直接成本，其余保持未分配。这样就能得到各产品线的贡献和一个诚实的共享成本池，比无人相信的完全吸收成本数字有用得多。
结果通常令人不适。大多数产品组合中少数几条产品线承担了全部负担，至少有一条长期产品线已亏损多年，而所有人还以为它在盈利。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 产品盈利能力仅被引用为公司层面在$62M ARR上的毛利率
✓ 尽管持续出现客户流失，却从未终止过任何产品
✓ 两人对同一产品线是否达到风险分成目标给出不同答案
通常会让情况更糟的做法。 按PMPM或注册成员将间接费用完全吸收进产品线，得出一个基于任意规则的精确数字，却因为看起来严谨而被维护。
It is for you if you run or finance a digital health company and product profitability is quoted as a company-wide gross margin. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Matrix Strategy, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
针对手头的决策，几乎不需要。可追溯成本加一个未分配池就能给出排序，而排序才是你要采取行动的依据。完整的作业成本法往往是一项超过决策生命周期的项目。
明确说出来并为支持定价。一条亏损的产品线若真正拉动盈利收入，就是一项有名称的营销成本——只要有人做过这个决定，这就很合理。
每年一次，并在产品组合发生重大变化后重做。排序比具体数字更稳定，所以每次重做成本都会降低。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית